0001209191-21-059131.txt : 20211004 0001209191-21-059131.hdr.sgml : 20211004 20211004181127 ACCESSION NUMBER: 0001209191-21-059131 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210929 FILED AS OF DATE: 20211004 DATE AS OF CHANGE: 20211004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vieser Jaime CENTRAL INDEX KEY: 0001846045 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33038 FILM NUMBER: 211304376 MAIL ADDRESS: STREET 1: ONE FIRST AVENUE, PARRIS BUILDING 34 STREET 2: NAVY YARD PLAZA CITY: BOSTON STATE: MA ZIP: 02129 FORMER NAME: FORMER CONFORMED NAME: Vieser Jamie DATE OF NAME CHANGE: 20210212 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ZIOPHARM ONCOLOGY INC CENTRAL INDEX KEY: 0001107421 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841475642 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE FIRST AVENUE STREET 2: PARRIS BUILDING 34, NAVY YARD PLAZA CITY: BOSTON STATE: MA ZIP: 02129 BUSINESS PHONE: 617-259-1970 MAIL ADDRESS: STREET 1: ONE FIRST AVENUE STREET 2: PARRIS BUILDING 34, NAVY YARD PLAZA CITY: BOSTON STATE: MA ZIP: 02129 FORMER COMPANY: FORMER CONFORMED NAME: EASYWEB INC DATE OF NAME CHANGE: 20010213 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-29 0 0001107421 ZIOPHARM ONCOLOGY INC ZIOP 0001846045 Vieser Jaime C/O ZIOPHARM ONCOLOGY, INC. ONE FIRST AVENUE, PARRIS BLDG 34 BOSTON MA 02129 1 0 0 0 Common Stock 2021-09-29 4 P 0 100000 1.91 A 705321 D Common Stock 100000 I By UTMA for child Common Stock 75000 I By UTMA for child Common Stock 75000 I By UTMA for child Common Stock 75000 I By UTMA for child The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ Kevin Lafond, Attorney-in-Fact 2021-10-04